Patent Claims

1. Use of an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1 for the manufacture of a medicament for treating cancer in a subject, wherein the cancer is lung cancer, bladder cancer, squamous cell carcinoma of the head and neck, renal cell carcinoma, gastric cancer, Merkel cell carcinoma, gastric / gastroesophageal junction cancer, breast cancer, colorectal cancer, castration-resistant prostate cancer, melanoma, ovarian cancer, adrenocortical carcinoma, mesothelioma, esophageal squamous cell carcinoma (ESCC), thymoma, adrenocortical carcinoma or urothelial carcinoma, and wherein the subject has previously received chemotherapy and/or radiotherapy.